OptiBiotix Health PLC’s (LON:OPTI) ProBiotix Health business has inked a distribution deal in the UK that will help expand the market for two of its key products.
The non-exclusive agreement with Cambridge Commodities (CCL) covers the specialty ingredient LPLDL and the finished dietary supplement CholBiomex3
CCL is a supplier of nutritional ingredients to major UK retailers and supplement companies.
OptiBiotix said the tie-up extends the commercial reach of LPLDL into new application areas where CCL has “specific sector expertise”, such as food and beverage, sports nutrition, health & wellbeing and beauty.
It also builds on the existing relationship with CCL, which led to the successful launch of the company’s weight management product SlimBiome in Holland and Barrett.
Mikkel Hvid-Hansen, commercial director of OptiBiotix’s ProBiotix Health arm, said CCL was chosen because of its “leading market position and expertise in commercialising value-added specialty ingredients” such as LPLDL and CholBiomex3 to major UK retailers and supplement companies.
“We believe working with CCL, and similar partners around the world, provides the best opportunity to expand the range of applications for LPLDL and CholBiomex3 to a wide variety of industry sectors,” he added.
“This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors.”